Maze Therapeutics Inc (MAZE)

$45.54 +1.32 (2.99%)
Market Cap 2.13B
Revenue (ttm) 167.50M
Net Income (ttm) 52.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 31.18%
Debt to Equity Ratio 0.00
Volume 378,300
Avg Vol 466,492
Day's Range N/A - N/A
Shares Out 48.12M
Stochastic %K 48%
Beta N/A
Analysts Strong Sell
Price Target $50.78

Company Profile

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 850 5070
Address:
171 Oyster Point Blvd, Suite 300, South San Francisco, United States
aldo_orderline
aldo_orderline Feb. 23 at 8:48 PM
$MAZE biotech volatility compressing if buyers reclaim resistance with size
0 · Reply
EmproX
EmproX Feb. 23 at 12:29 PM
$MAZE $AGRZ $BTOC $HPP ~~
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 21 at 2:33 AM
$MAZE RSI: 51.66, MACD: 0.8850 Vol: 1.61, MA20: 45.77, MA50: 42.77 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 16 at 12:23 PM
$MAZE Current Stock Price: $46.00 Contracts to trade: $45.0 MAZE Feb 20 2026 Call Entry: $0.10 Exit: $0.13 ROI: 35% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Merlintrader
Merlintrader Feb. 10 at 12:55 PM
$MAZE Maze Therapeutics: MZE829 Phase 2 Readout & Guggenheim Biotech Summit 2026 | Daily Hit https://www.merlintrader.com/maze-therapeutics-inc/
0 · Reply
DARKP00L
DARKP00L Feb. 4 at 11:26 PM
$MAZE 17:29 on Feb. 04 2026 Maze Therapeutics Files For Mixed Shelf; Size Not Disclosed #tradeideas
1 · Reply
GalacticGamma
GalacticGamma Feb. 4 at 9:53 AM
$MAZE biotech, pre-clinical stage
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 30 at 1:24 AM
$MAZE Current Stock Price: $44.97 Contracts to trade: $45 MAZE Feb 20 2026 Call Entry: $1.05 Exit: $1.72 ROI: 64% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
DailyAnalysis
DailyAnalysis Jan. 20 at 8:29 PM
$MAZE exhibits embedded momentum. RSI holding 60 invalidates bearish divergence, while CCI piercing 100 signals volatility expansion. With Stoch staying overbought, the trend is aggressive, not exhausted. Don't fade this strength. @DailyAnalysis
0 · Reply
StockConsultant
StockConsultant Jan. 20 at 4:35 PM
$MAZE Maze Therapeutics stock with a narrow range breakout, volume +50% at https://stockconsultant.com/?MAZE
1 · Reply
Latest News on MAZE
Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Feb 4, 2026, 7:00 AM EST - 19 days ago

Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Maze Therapeutics: An Innovative, Nature-Driven Platform

Jan 16, 2026, 3:35 AM EST - 5 weeks ago

Maze Therapeutics: An Innovative, Nature-Driven Platform

Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 7:00 AM EST - 7 weeks ago

Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Maze Therapeutics, Inc. (MAZE) Presents at Jefferies London Healthcare Conference 2025 Prepared Remarks Transcript

Nov 25, 2025, 9:43 AM EST - 3 months ago

Maze Therapeutics, Inc. (MAZE) Presents at Jefferies London Healthcare Conference 2025 Prepared Remarks Transcript

Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Nov 6, 2025, 4:01 PM EST - 3 months ago

Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week

Nov 6, 2025, 7:00 AM EST - 3 months ago

Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week

Maze Therapeutics to Participate in Four Upcoming Investor Conferences

Nov 4, 2025, 7:00 AM EST - 3 months ago

Maze Therapeutics to Participate in Four Upcoming Investor Conferences

Maze Therapeutics CEO Jason Coloma on how the new biotech is taking on Kidney disease

Oct 28, 2025, 4:27 PM EDT - 4 months ago

Maze Therapeutics CEO Jason Coloma on how the new biotech is taking on Kidney disease

San Francisco is making a comeback. So are these stocks from the City by the Bay

Oct 28, 2025, 12:36 PM EDT - 4 months ago

San Francisco is making a comeback. So are these stocks from the City by the Bay

NKTR REAL

Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors

Oct 6, 2025, 7:00 AM EDT - 5 months ago

Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors

Maze Therapeutics, Inc. (MAZE) Discuses On MZE782 Phase 1 Healthy Volunteer Trial Results Call (Transcript)

Sep 11, 2025, 7:25 PM EDT - 5 months ago

Maze Therapeutics, Inc. (MAZE) Discuses On MZE782 Phase 1 Healthy Volunteer Trial Results Call (Transcript)

Maze Shares Jump As Investors Bet Big On Experimental Treatment's Potential

Sep 11, 2025, 2:05 PM EDT - 5 months ago

Maze Shares Jump As Investors Bet Big On Experimental Treatment's Potential

Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement

Sep 11, 2025, 7:35 AM EDT - 5 months ago

Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement

Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)

Sep 11, 2025, 7:30 AM EDT - 5 months ago

Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)

Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer

Sep 2, 2025, 7:00 AM EDT - 6 months ago

Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer

National Advertising Division Refers Maze Therapeutics to Regulatory Authorities for Failure to Respond to Inquiry

Aug 27, 2025, 11:31 AM EDT - 6 months ago

National Advertising Division Refers Maze Therapeutics to Regulatory Authorities for Failure to Respond to Inquiry

Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Aug 12, 2025, 4:01 PM EDT - 6 months ago

Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Maze Therapeutics to Participate in Two Upcoming Investor Conferences

Jul 10, 2025, 4:05 PM EDT - 8 months ago

Maze Therapeutics to Participate in Two Upcoming Investor Conferences

Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference

May 29, 2025, 7:30 AM EDT - 9 months ago

Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference

Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones

May 14, 2025, 4:01 PM EDT - 10 months ago

Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones

Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference

May 13, 2025, 7:30 AM EDT - 10 months ago

Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference

Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights

Mar 31, 2025, 7:30 AM EDT - 11 months ago

Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights

Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease

Feb 7, 2025, 8:00 AM EST - 1 year ago

Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease

U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs

Feb 1, 2025, 2:10 AM EST - 1 year ago

U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs

BBNX CSAI INR MTSR ODTX ODYS SAIL

Maze Therapeutics valued at $690.4 million as shares rise marginally in market debut

Jan 31, 2025, 12:33 PM EST - 1 year ago

Maze Therapeutics valued at $690.4 million as shares rise marginally in market debut

Biotech firm Maze Therapeutics raises $140 million in US IPO

Jan 30, 2025, 7:45 PM EST - 1 year ago

Biotech firm Maze Therapeutics raises $140 million in US IPO

Maze Therapeutics Announces Pricing of Upsized Initial Public Offering

Jan 30, 2025, 7:30 PM EST - 1 year ago

Maze Therapeutics Announces Pricing of Upsized Initial Public Offering

Maze Therapeutics targets up to $728 mln valuation in US IPO

Jan 27, 2025, 6:31 AM EST - 1 year ago

Maze Therapeutics targets up to $728 mln valuation in US IPO

Maze Therapeutics Seeks IPO For Trials Ramp-Up

Jan 13, 2025, 12:07 PM EST - 1 year ago

Maze Therapeutics Seeks IPO For Trials Ramp-Up

aldo_orderline
aldo_orderline Feb. 23 at 8:48 PM
$MAZE biotech volatility compressing if buyers reclaim resistance with size
0 · Reply
EmproX
EmproX Feb. 23 at 12:29 PM
$MAZE $AGRZ $BTOC $HPP ~~
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 21 at 2:33 AM
$MAZE RSI: 51.66, MACD: 0.8850 Vol: 1.61, MA20: 45.77, MA50: 42.77 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 16 at 12:23 PM
$MAZE Current Stock Price: $46.00 Contracts to trade: $45.0 MAZE Feb 20 2026 Call Entry: $0.10 Exit: $0.13 ROI: 35% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Merlintrader
Merlintrader Feb. 10 at 12:55 PM
$MAZE Maze Therapeutics: MZE829 Phase 2 Readout & Guggenheim Biotech Summit 2026 | Daily Hit https://www.merlintrader.com/maze-therapeutics-inc/
0 · Reply
DARKP00L
DARKP00L Feb. 4 at 11:26 PM
$MAZE 17:29 on Feb. 04 2026 Maze Therapeutics Files For Mixed Shelf; Size Not Disclosed #tradeideas
1 · Reply
GalacticGamma
GalacticGamma Feb. 4 at 9:53 AM
$MAZE biotech, pre-clinical stage
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 30 at 1:24 AM
$MAZE Current Stock Price: $44.97 Contracts to trade: $45 MAZE Feb 20 2026 Call Entry: $1.05 Exit: $1.72 ROI: 64% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
DailyAnalysis
DailyAnalysis Jan. 20 at 8:29 PM
$MAZE exhibits embedded momentum. RSI holding 60 invalidates bearish divergence, while CCI piercing 100 signals volatility expansion. With Stoch staying overbought, the trend is aggressive, not exhausted. Don't fade this strength. @DailyAnalysis
0 · Reply
StockConsultant
StockConsultant Jan. 20 at 4:35 PM
$MAZE Maze Therapeutics stock with a narrow range breakout, volume +50% at https://stockconsultant.com/?MAZE
1 · Reply
TradeTracs
TradeTracs Jan. 20 at 6:07 AM
$MAZE double inside day with 50sma daily tracking below. Weekly 10ema tracking tightly to PLOW. Healthtech name w sub avg Vol.
0 · Reply
TradeTracs
TradeTracs Jan. 15 at 7:37 PM
$MAZE - Strong sector and theme - Strong relative strength - Respecting support
0 · Reply
JohannFrancois
JohannFrancois Jan. 1 at 7:16 AM
$MAZE $CMPX has anyone done DD on these two companies and are they worth putting money on? I’ve done a limited amount of DD on both, pretty favorable run up in terms of good management track record and cash run way. they have binary catalyst event coming up Q1 2026, just want to know if anyone are bullish too?
0 · Reply
Quantumup
Quantumup Dec. 30 at 1:19 PM
Guggenheim reiterated $UNCY Buy/$46 $SNY $MAZE $TVTX $TAK ARDX AKBA Here's what Guggenheim had to say: https://x.com/Quantumup1/status/2005990714652364820?s=20
1 · Reply
TelecomTower
TelecomTower Dec. 25 at 4:24 PM
$MAZE Macro forces may influence direction, yet internal execution remains the decisive factor. Cash flow visibility will determine how patient investors remain. Smart capital allocation could unlock optionality not yet reflected. Execution precision will determine whether this evolves or stalls.
0 · Reply
JarvisFlow
JarvisFlow Dec. 4 at 1:39 PM
Wells Fargo has adjusted their stance on Maze Therapeutics ( $MAZE ), setting the rating to Overweight with a target price of 55.
0 · Reply
JarvisFlow
JarvisFlow Dec. 3 at 7:18 PM
HC Wainwright & Co. has adjusted their stance on Maze Therapeutics ( $MAZE ), setting the rating to Buy with a target price of 50 → 60.
0 · Reply
Godwins26
Godwins26 Dec. 3 at 6:29 PM
3rd Watchlist today 😊 $PLRZ $ARWR $MAZE $BEAM $IMNM
0 · Reply
GregRiskTaker
GregRiskTaker Nov. 28 at 8:42 PM
$MAZE Im so amaze with myself sold today at $.597 and bought back in $.4499 Nothing like free shares, thank you so much, have such a blessed weekend. What a great day today with AMZE, BEAT, KTTA and LAES Next week will be off the hook with AMZE $.75 on radar.
0 · Reply
Quantumup
Quantumup Nov. 13 at 9:12 PM
Raymond James🏁 $MAZE Outperform/$48 $VRTX $UNCY $OTSKY Raymond James said: The Maze Compass platform leverages genetic insights to discover novel therapies for genetically validated targets. MAZE's lead wholly-owned assets target high unmet need chronic kidney disease (CKD) populations: MZE829, an oral APOL1 inhibitor in Phase 2 for APOL1-mediated kidney disease (AMKD), and MZE782, an oral SLC6A19 inhibitor entering Phase 2 in phenylketonuria (PKU) and CKD. Both assets have best-in-class potential in attractive commercial indications and encouraging early mechanistic de-risking, in our view. While shares have roughly doubled from the January 2025 IPO, we believe MAZE continues to offer a very compelling risk/ reward skew into key Phase 2 readouts for MZE829 and MZE782 beginning in 2026.
0 · Reply